A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

NCT01708161 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

PIK3CA Mutated Advanced Solid Tumors
PIK3CA Amplified Advanced Solid Tumors

Interventions

DRUG: BYL719
DRUG: AMG 479

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]